| abstract |
The present disclosure relates to an administration scheme for a thrombopoietin receptor agonist. Specifically, provided in the present disclosure is a method for treating thrombocytopenia, comprising administering to a patient a therapeutically effective amount of a compound as represented by formula I or a pharmaceutically acceptable salt thereof, wherein the compound as represented by formula I or the pharmaceutically acceptable salt thereof, which is administered to the patient, does not have a drug-drug interaction with a BCRP substrate in the patient. |